Mon Sep 23 18:19:39 UTC 2024: ## Bausch + Lomb Stock Gets a Boost: HC Wainwright Raises Target Price to $22

**New York, NY – September 23, 2024** – Bausch + Lomb (NYSE: BLCO) is on the rise, with investment firm HC Wainwright boosting its target price for the eye health company from $19.00 to $22.00. This represents a potential upside of 11.56% from the company’s current price. HC Wainwright maintains a “buy” rating on the stock.

The positive outlook from HC Wainwright follows a trend of analysts expressing confidence in Bausch + Lomb. Stifel Nicolaus recently increased its price target to $19.00, while Evercore ISI lifted its target price to $15.50. Royal Bank of Canada reaffirmed its “outperform” rating with a $20.00 price target.

Bausch + Lomb recently reported strong second-quarter earnings, exceeding analyst expectations with $0.13 earnings per share and revenue of $1.22 billion. The company’s year-over-year revenue growth was 17.5%.

Adding to the positive sentiment, CEO Brent L. Saunders purchased 32,250 shares of Bausch + Lomb stock, demonstrating his confidence in the company’s future. Institutional investors are also showing interest, with hedge funds like Clearline Capital LP, Freshford Capital Management LLC, and Whitebox Advisors LLC increasing their holdings in the company.

Bausch + Lomb operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment, which offers contact lenses and care products, is a key driver of the company’s growth.

The company’s strong financial performance, positive analyst outlook, and increased institutional interest suggest a bright future for Bausch + Lomb. Investors are keeping a close eye on the company’s performance as it continues to navigate the competitive eye health market.

Read More